The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics

Journal of Asthma

Volumn 40, Issue 3, 2003, Pages 257-264

  Fukuoka, Toshihiko ^a   Miyake, Shuji ^a   Umino, Takeshi ^a   Inase, Naohiko ^a   Tojo, Naoko ^a   Yoshizawa, Yasuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Asthma; Astograph; ECP; Seratrodast

Indexed keywords

ACETYLCHOLINE; BECLOMETASONE DIPROPIONATE; CLENBUTEROL; EOSINOPHIL CATIONIC PROTEIN; PROCATEROL; SERATRODAST; THEOPHYLLINE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PEAK EXPIRATORY FLOW; PROTEIN BLOOD LEVEL; SERUM; SPUTUM ANALYSIS; SPUTUM LEVEL; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZOQUINONES; BLOOD PROTEINS; BRONCHIAL HYPERREACTIVITY; CROSS-OVER STUDIES; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION MEDIATORS; MALE; PEAK EXPIRATORY FLOW RATE; RIBONUCLEASES; SPUTUM; THROMBOXANE A2;

EID: 0037610262     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120018322     Document Type: Article

References (29)

1. NHLBI, WHO. Global Initiative for Asthma, 95-3659. Washington, DC: National Institutes of Health, 1995.
2. Barnes NC, de Jong B, Miyamoto T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997; 111(2 suppl):52S.
3. Tamaoki J, Kondo M, Sakai N, Aoshiba K, Tagaya E, Nakata J, Isono K, Nagai A. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Lancet 2000; 356(9226):273.
4. Devillier P, Bessard G. Thromboxane A2 and related prostaglandins in airways. Fundam Clin Pharm 1997; 11(1):2.
5. Kurokawa T, Matsumoto T, Ashida Y, Sasada R, Iwasa S. Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414. Biol Pharm Bull 1994; 17(3):383.
6. Kawikova I, Arakawa H, Skoogh BE, Lofdahl CG, Lotvall J. U46619 (a thromboxane A2 mimetic) induces airflow obstruction and airway plasma extravasation in the guinea pig: the role of histamine, cyclooxygenase metabolites, leukotrienes and PAF. J Pharmacol Exp Ther 1996; 278(1):268.
7. Fujimura M, Abo M, Kamio Y, Myou S, Ishiura Y, Hashimoto T, Matsuda T. Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. Am J Respir Crit Care 1999; 160(6):2100.
8. Hoshino M, Sim J, Shimizu K, Nakayama H, Koya A. Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. J Allergy Clin Immun 1999; 103(6):1054.
9. Aizawa H, Inoue H, Nakano H, Matsumoto K, Yoshida M, Fukuyama S, Koto H, Hara N. Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitricoxide, and induced sputum eosinophils in asthmatics. Prostag Leukotr Ess 1998; 59(3):185.
10. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allerg 1999; 29(9):1172.
11. Konno S, Gonokami Y, Kurokawa M, Kawazu K, Asano K, Okamoto K, Adachi M. Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Imm 1996; 109(1):73.
12. Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest 1997; 112(5):1241.
13. Gibson PG, Woolley KL, Carty K, Murree-Allen K, Saltos N. Induced sputum eosinophil cationic protein (ECP) measurement in asthma and chronic obstructive airway disease (COAD) [see comments]. Clin Exp Allerg 1998; 28(9):1081.
14. Virchow JC Jr, Holscher U, Virchow C Sr. Sputum ECP levels correlate with parameters of airflow obstruction. Am Rev Respir Dis 1992; 146(3):604.
15. Takishima T, Hida W, Sasaki H, Suzuki S, Sasaki T. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest 1981; 80(5):600.
16. Adachi T, Motojima S, Hirata A, Fukuda T, Makino S. Eosinophil viability-enhancing activity in sputum from patients with bronchial asthma, Contributions of interleukin-5 and granulocyte/macrophage colony-stimulating factor. Am J Respir Crit Care 1995; 151(3 Pt 1):618.
17. Bousquet J, Chanez P, Vignola AM, Lacoste JY, Michel FB. Eosinophil inflammation in asthma. Am J Respir Crit Care 1994; 150(5 Pt 2):S33.
18. Jeffery PK. Comparative morphology of the airways in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care 1994; 150(5 Pt 2):S6.
19. Bentley AM, Menz G, Storz CHR, Robinson DS, Bradley B, Jeffery PK, Durham SR, Kay AB. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Am Rev Respir Dis 1992; 146(2):500.
20. Ohashi Y, Motojima S, Fukuda T, Makino S. Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma [see comments]. Am Rev Respir Dis 1992; 145(6):1469.
21. Wong HH, Fahy JV. Safety of one method of sputum induction in asthmatic subjects. Am J Respir Crit Care 1997; 156(1):299.
22. in't Veen JC, de Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ, Bel EH. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma [see comments]. Eur Respir J 1996; 9(12):2441.
23. Spanevello A, Migliori GB, Sharara A, Ballardini L, Bridge P, Pisati P, Neri M, Ind PW. Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allerg 1997; 27(10):1138.
24. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immun 1999; 103(2 Pt 1):232.
25. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care 1996; 154(2 Pt 1):308.
26. Fahy JV, Wong H, Liu J, Boushey HA. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care 1995; 152(1):53.
27. Bacci E, Cianchetti S, Paggiaro PL, Carnevali S, Bancalari L, Dente FL, Di Franco A, Giannini D, Vagaggini B, Giuntini C. Comparison between hypertonic and isotonic saline-induced sputum in the evaluation of airway inflammation in subjects with moderate asthma. Clin Exp Allerg 1996; 26(12):1395.
28. Hargreave FE. The investigation of airway inflammation in asthma: sputum examination. Clin Exp Allerg 1997; 27(Suppl 1):36.
29. Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47(1):25.